← Eichor
Study identifier: NCT05620732 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T

Condition: Advanced Pancreatic Carcinoma · Advanced Gastric Carcinoma  ·  Sponsor: Shenzhen University General Hospital

PhaseNA
Planned participants20
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The efficacy of advanced pancreatic cancer and gastric cancer needs to be further improved. Claudin is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in gastric cancer and pancreatic cancer. Preclinical studies suggest that Claudin18.2CAR-T can effectively improve the remission rate of patients with advanced solid tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Li Yu, Dr  ·  +8675521839178  ·  liyu@vip.163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Li YuShenzhen, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05620732